Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1519-1528

  Bilezikian, John P ^a   Josse, Robert G ^b   Eastell, Richard ^c   Lewiecki, E Michael ^d   Miller, Colin G ^e   Wooddell, Margaret ^f   Northcutt, Allison R ^f   Kravitz, Barbara G ^f   Paul, Gitanjali ^f   Cobitz, Alexander R ^f   Nino, Antonio J ^f   Fitzpatrick, Lorraine A ^f  

^a Columbia University ^*  (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e BioClinica Inc   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; VITAMIN D;

ADULT; AGED; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CALCIUM HOMEOSTASIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; EXERCISE; FATIGUE; FEMALE; FEMUR; FEMUR NECK; FINGER FRACTURE; FRACTURE; FRACTURE RISK; GLYCEMIC CONTROL; HIGH RISK PATIENT; HIP; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEG FRACTURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PERIPHERAL EDEMA; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TROCHANTER; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE REMODELING; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG SUBSTITUTION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; POSTMENOPAUSE; THIAZOLIDINEDIONES;

EID: 84876277969     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4018     Document Type: Article

References (54)

1. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin EndocrinolMetab. 2006; 91: 3404-3410.
2. Schwartz AV, Sellmeyer DE, Ensrud EK, et al; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001; 86: 32-38.
3. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 1999; 22: 1196-1200.
4. Barrett-Connor E, Holbrook TL. Sex difference in osteoporosis in older adults with non-insulin-dependent diabetes mellitus JAMA. 1992; 268: 3333-3337.
5. Nicodemus KK, Folsom AR. Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001; 24: 1192-1197.
6. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systemic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166: 495-505.
7. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007; 18: 427-444.
8. Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2011; 27: 301-308.
9. Kahn SE, Zinman B, Lachin JM, et al; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31: 845-851.
10. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-2135.
11. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32: 187-202.
12. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus. Dear Healthcare Provider letter from Takeda Pharmaceuticals North America, Inc. http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153896.pdf. Published March 2007. Accessed September 3, 2012.
13. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci. 1992; 102: 341-351.
14. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996; 50: 1087-1094.
15. Nuttall ME, Gimble JM. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone. 2000; 27: 177-184.
16. Rosen ED. The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids. 2005; 73: 31-34.
17. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004; 145: 401-406.
18. Gruntmanis U, Fordan S, Ghayee HK, et al. The peroxisome proliferator-activated receptor-y agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int. 2010; 86: 343-349.
19. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARy agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004; 75: 329-337.
20. Wan Y, Chong LW, Evans RM. PPAR-y regulates osteoclastogenesis in mice. Nat Med. 2007; 13: 1496-1503.
21. Bruedigam C, Driel M, Koedam M, et al. Basic techniques in human mesenchymal stem cell cultures: differentiation into osteogenic and adipogenic lineages, genetic perturbations, and phenotypic analyses. Curr Protoc Stem Cell Biol. 2011; Chapter 1: Unit1H.3.
22. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2: 35-43.
23. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot GeneExpr. 2009; 19: 109-124.
24. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol. 2009; 160: 265-273.
25. Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010; 159: 61-66.
26. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: 234-241.
27. Jeyabalan J, Shah M, Viollet B, Chenu C. AMP-activated protein kinase pathway and bone metabolism. J Endocrinol. 2012; 212: 277-290.
28. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem. 2007; 102: 1343-1357.
29. Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone. 2009; 45: S35-S38.
30. Manavalan JS, Cremers DW, Dempster DW, et al. Circulating osteoblast precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: 3240-3250.
31. Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006; 17: 986-995.
32. Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006; 79: 160-168.
33. Ogawa N, Yamaguchi T, Yano S, Yamaguchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advance glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells though glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007; 39: 871-875.
34. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008; 93: 1013-1019.
35. Seto-Young D, Avtanski D, Parikh G, et al. Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res. 2011; 43: 250-256.
36. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol. 2006; 536: 38-46.
37. Zinman B, Haffner SM, Herman WH, et al; ADOPT Study Group. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010; 95: 134-142.
38. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008; 31: 199-203.
39. Dempster DW. Anatomy and functions of the adult skeleton. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Bone Metabolism. 6th ed. Washington DC: The American Society for Bone and Mineral Research; 2006; 7-11.
40. Fitzpatrick LA, Bilezikian JP, Wooddell M, et al. Mechanism of action study to evaluate the effect of rosiglitazone on bone in postmenopausal women with type 2 diabetes mellitus: rationale, study design and baseline characteristics. J Drug Assess. 2012; 1: 11-19.
41. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004; 27: 1487-1495.
42. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab. 2007; 92: 3523-3530.
43. Cutrim DM, Pereira FA, de Paula FJ, Foss MC. Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz J Med Biol Res. 2007; 40: 221-227.
44. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract. 1994; 23: 43-54.
45. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 1995; 122: 409-414.
46. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002; 25: 1749-1754.
47. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci. 2005; 60: 1157-1162.
48. Akune T, Ohbe S, Kamekura S, et al. PPARy insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113: 846-855.
49. Bruedigam C, Eijken M, Koedam M, et al. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells. 2010; 28: 916-927.
50. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443.
51. Rosenstock J, Goldstein BJ, Vinik AI, et al; RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006; 8: 49-57.
52. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1277-1284.
53. Paula FJ, Lanna CM, Shuhama T, Foss MC. Effect of metabolic control on parathyroid hormone secretion in diabetic patients. Braz J Med Biol Res. 2001; 34: 1139-1145.
54. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-y agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007; 92:1305-1310.